Lars Olson

Karolinska Institute, Stockholm, Sweden 
"Lars Olson"
Mean distance: 15.34 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Glotfelty EJ, Tovar-Y-Romo LB, Hsueh SC, et al. (2023) The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia. Cells. 12
Glotfelty EJ, Hsueh SC, Claybourne Q, et al. (2023) Microglial Nogo delays recovery following traumatic brain injury in mice. Glia
Kuo TT, Chen YH, Wang V, et al. (2023) PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. International Journal of Molecular Sciences. 24
Tseng KY, Kuo TT, Wang V, et al. (2022) Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. Journal of Parkinson's Disease
Wang V, Kuo TT, Huang EY, et al. (2021) Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. Acs Pharmacology & Translational Science. 4: 858-869
Glotfelty EJ, Olson L, Karlsson TE, et al. (2020) Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opinion On Investigational Drugs. 1-8
Chen YH, Wang V, Huang EY, et al. (2019) Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice. International Journal of Molecular Sciences. 20
Li Y, Glotfelty EJ, Namdar I, et al. (2019) Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology. 113113
Ross JM, Coppotelli G, Branca RM, et al. (2019) Voluntary exercise normalizes the proteomic landscape in muscle and brain and improves the phenotype of progeroid mice. Aging Cell. e13029
Glotfelty EJ, Delgado T, Tovar-Y-Romo LB, et al. (2019) Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. Acs Pharmacology & Translational Science. 2: 66-91
See more...